What is the role of TMP-SMX in Pneumocystis jirovecii pneumonia prophylaxis in HIV, and what safety concerns require monitoring?

• A. Not used for PCP; monitor for nephrotoxicity only
• B. Second-line therapy; monitor for nephrotoxicity and hypertension
• C. First-line prophylaxis; monitor for hyperkalemia, cytopenias, and renal function
• D. Alternative therapy; monitor for nephrotoxicity only

Answer: (C)

TMP-SMX is the first-line prophylaxis for Pneumocystis jirovecii pneumonia in people with HIV, especially when the CD4 count is below 200 cells/µL or after a PCP episode. Its high efficacy, convenience (oral dosing), and broad protection make it the default preventive therapy. Safety monitoring is essential because TMP-SMX can cause hyperkalemia (trimethoprim can raise potassium by acting like a potassium-sparing diuretic, particularly with kidney disease or competing medications), cytopenias (bone marrow suppression leading to anemia, leukopenia, or thrombocytopenia due to the folate pathway inhibition), and renal function changes (nephrotoxicity and increases in creatinine). So clinicians routinely check electrolytes, especially potassium, monitor complete blood counts, and assess renal function (creatinine/eGFR) while the patient is on prophylaxis. If any of these safety issues arise, alternatives may be considered, but as prophylaxis, TMP-SMX is preferred with appropriate monitoring.